An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

Yoshinobu Maeda, Hisakazu Nishimori, Yoshihiro Inamoto, Hirohisa Nakamae, Masashi Sawa, Yasuo Mori, Kazuteru Ohashi, Shin ichiro Fujiwara, Mitsune Tanimoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

Original languageEnglish
Pages (from-to)409-412
Number of pages4
JournalActa medica Okayama
Volume70
Issue number5
Publication statusPublished - 2016

Keywords

  • Am80
  • Chronic GVHD
  • Retinoid
  • Steroid-refractory GVHD
  • Tamibarotene

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease'. Together they form a unique fingerprint.

  • Cite this

    Maeda, Y., Nishimori, H., Inamoto, Y., Nakamae, H., Sawa, M., Mori, Y., Ohashi, K., Fujiwara, S. I., & Tanimoto, M. (2016). An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease. Acta medica Okayama, 70(5), 409-412.